Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Leptomeningeal Metastases: early-phase trial registry
1 of 4 indexed Leptomeningeal Metastases trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #4,115 of 28,707 conditions by registered trial count.
4 US clinical trials · 1 currently recruiting · #4,115 of 28,707 conditions by registered trial count
Leptomeningeal Metastases: 4 US clinical trials tracked, 1 recruiting.
Leptomeningeal Metastases is the subject of 4 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most active sponsor is Memorial Sloan Kettering Cancer Center, running 3 of these trials.
Enrollment posture brief
Registry condition leptomeningeal-metastases
OPEN 1 | RECR 25% | LATE 0 | EARLY 4 | RANK #4115 | SPON 3
Volume-matched condition peers
Nearest open-share peer: Abdominal Cancer (25% recruiting · 8 trials)
Leptomeningeal Metastases lists 1 open slots (25% of 4 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Leptomeningeal Metastases on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Leptomeningeal Metastases is recruiting below its size-band peers.
1 of 4 indexed trials (25%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
4 total, page 1 of 1
A Study of Deferoxamine (DFO) in People With Leptomeningeal Metastasis
Memorial Sloan Kettering Cancer Center
NCT05184816
Proton Craniospinal Radiation Therapy vs. Partial Photon Radiation Therapy for Leptomeningeal Metastasis From Solid Tumors
Memorial Sloan Kettering Cancer Center
NCT04343573
Phase 2 Study of Study of Tesevatinib in Subjects With NSCLC and Brain or Leptomeningeal Metastases
Kadmon Corporation
NCT02616393
Study of Proton Radiation to the Brain and Spinal Cord for Patients With Leptomeningeal Metastases
Memorial Sloan Kettering Cancer Center
NCT03520504
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Leptomeningeal Metastases records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Leptomeningeal Metastases trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Leptomeningeal Metastases page
4 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 Leptomeningeal Metastases trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Memorial Sloan Kettering Cancer Center sponsors the most Leptomeningeal Metastases trials on record, review their full trial history before evaluating a specific study. See Memorial Sloan Kettering Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Leptomeningeal Metastases condition card totals 4 registered trials; most-linked intervention MDASI-BT and MDASI-SP; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.